NCT04413292View on ClinicalTrials.gov

Survivin and Fibulin-3 in Benign and Malignant Respiratory Diseases

CompletedOBSERVATIONAL
Enrollment

93

Participants

Timeline

Start Date

January 1, 2017

Primary Completion Date

December 30, 2019

Study Completion Date

April 1, 2020

Conditions
Bronchial Neoplasm Benign
Interventions
DIAGNOSTIC_TEST

ELISA assays and Westren blot analysis of survivin and fibulin-3 expression

expression analysis of biomarkers

All Listed Sponsors
lead

South Valley University

OTHER

NCT04413292 - Survivin and Fibulin-3 in Benign and Malignant Respiratory Diseases | Biotech Hunter | Biotech Hunter